Adverum Biotechnologies Inc. (ADVM) is priced at $12.20 after the most recent trading session. At the very opening of the session, the stock price was $11.93 and reached a high price of $12.28, prior to closing the session it reached the value of $11.99. The stock touched a low price of $11.66.
Recently in News on August 18, 2020, Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock. Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the closing of its previously announced underwritten public offering of 16,675,000 shares of its common stock at a public offering price of $13.00 per share, which included the full exercise of the underwriters’ option to purchase up to an additional 2,175,000 shares of common stock. The gross proceeds to Adverum before deducting underwriting discounts and commissions and offering expenses payable by Adverum were approximately $216.8 million. You can read further details here
Adverum Biotechnologies Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $26.98 on 06/23/20, with the lowest value was $7.36 for the same time period, recorded on 03/12/20.
Adverum Biotechnologies Inc. (ADVM) full year performance was 18.10%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Adverum Biotechnologies Inc. shares are logging -54.78% during the 52-week period from high price, and 145.97% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $4.96 and $26.98.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 791387 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Adverum Biotechnologies Inc. (ADVM) recorded performance in the market was 5.90%, having the revenues showcasing -42.23% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.16B, as it employees total of 114 workers.
The Analysts eye on Adverum Biotechnologies Inc. (ADVM)
During the last month, 0 analysts gave the Adverum Biotechnologies Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 17.72, with a change in the price was noted +1.47. In a similar fashion, Adverum Biotechnologies Inc. posted a movement of +13.70% for the period of last 100 days, recording 1,367,424 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ADVM is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Adverum Biotechnologies Inc. (ADVM)
Raw Stochastic average of Adverum Biotechnologies Inc. in the period of last 50 days is set at 4.52%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 9.03%. In the last 20 days, the company’s Stochastic %K was 6.05% and its Stochastic %D was recorded 6.72%.
Considering, the past performance of Adverum Biotechnologies Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 5.90%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -4.54%, alongside a boost of 18.10% for the period of the last 12 months. The shares increased approximately by -2.40% in the 7-day charts and went up by -27.25% in the period of the last 30 days. Common stock shares were lifted by -42.23% during last recorded quarter.